Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Mar;27(3):281–284. doi: 10.1111/j.1365-2125.1989.tb05365.x

The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

G T McInnes 1
PMCID: PMC1379823  PMID: 2719892

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amdisen A. Serum concentration and clinical supervision in monitoring of lithium treatment. Ther Drug Monit. 1980;2(1):73–83. doi: 10.1097/00007691-198001000-00009. [DOI] [PubMed] [Google Scholar]
  2. Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet. 1977 Mar-Apr;2(2):73–92. doi: 10.2165/00003088-197702020-00001. [DOI] [PubMed] [Google Scholar]
  3. Aronson J. K., Grahame-Smith D. G., Wigley F. M. Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med. 1978 Apr;47(186):111–122. [PubMed] [Google Scholar]
  4. Arroyo J. C., Milligan W. L., Davis J., Mitchell D. Impact of aminoglycoside serum assays on clinical decisions and renal toxicity. South Med J. 1986 Mar;79(3):272–276. doi: 10.1097/00007611-198603000-00003. [DOI] [PubMed] [Google Scholar]
  5. Baastrup P. C., Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 1967 Feb;16(2):162–172. doi: 10.1001/archpsyc.1967.01730200030005. [DOI] [PubMed] [Google Scholar]
  6. Beasley R., Smith D. A., McHaffie D. J. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J (Clin Res Ed) 1985 Jan 5;290(6461):9–11. doi: 10.1136/bmj.290.6461.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brodie M. J., McIntosh M. E., Hallworth M. Therapeutic drug monitoring--the need for audit? Scott Med J. 1985 Apr;30(2):75–82. doi: 10.1177/003693308503000202. [DOI] [PubMed] [Google Scholar]
  8. Brodie M. J. Therapeutic drug monitoring. Practitioner. 1986 Nov;230(1421):1003–1009. [PubMed] [Google Scholar]
  9. Callaghan N., Garrett A., Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. N Engl J Med. 1988 Apr 14;318(15):942–946. doi: 10.1056/NEJM198804143181502. [DOI] [PubMed] [Google Scholar]
  10. Cawthorne I. F., Silas J. H. Impact of therapeutic audit on phenytoin prescribing. Br Med J (Clin Res Ed) 1981 Apr 18;282(6272):1278–1278. doi: 10.1136/bmj.282.6272.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davidson D. L. Anticonvulsant drugs. Br Med J (Clin Res Ed) 1983 Jun 25;286(6383):2043–2045. doi: 10.1136/bmj.286.6383.2043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Duhme D. W., Greenblatt D. J., Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med. 1974 Apr;80(4):516–519. doi: 10.7326/0003-4819-80-4-516. [DOI] [PubMed] [Google Scholar]
  13. Feldman R. G., Pippenger C. E. The relation of anticonvulsant drug levels to complete seizure control. J Clin Pharmacol. 1976 Jan;16(1):51–59. doi: 10.1002/j.1552-4604.1976.tb01491.x. [DOI] [PubMed] [Google Scholar]
  14. Flenley D. C. New drugs in respiratory disorders: I. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):871–875. doi: 10.1136/bmj.286.6368.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fogelman A. M., La Mont J. T., Finkelstein S., Rado E., Pearce M. L. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients. Lancet. 1971 Oct 2;2(7727):727–729. doi: 10.1016/s0140-6736(71)92100-3. [DOI] [PubMed] [Google Scholar]
  16. Friedman H., Greenblatt D. J. Rational therapeutic drug monitoring. JAMA. 1986 Oct 24;256(16):2227–2233. [PubMed] [Google Scholar]
  17. Gannaway D. J., Mawer G. E. Serum phenytoin concentration and clinical response in patients with epilepsy. Br J Clin Pharmacol. 1981 Dec;12(6):833–839. doi: 10.1111/j.1365-2125.1981.tb01316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. George C. F. Digitalis intoxication: a new approach to an old problem. Br Med J (Clin Res Ed) 1983 May 14;286(6377):1533–1534. doi: 10.1136/bmj.286.6377.1533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. George C. F. Interactions with digoxin: more problems. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):291–292. doi: 10.1136/bmj.284.6312.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gibb I., Cowan J. C., Parnham A. J., Thomas T. H. Use and misuse of a digoxin assay service. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):678–680. doi: 10.1136/bmj.293.6548.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goldman S., Probst P., Selzer A., Cohn K. Inefficacy of "therapeutic" serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol. 1975 May;35(5):651–655. doi: 10.1016/0002-9149(75)90051-x. [DOI] [PubMed] [Google Scholar]
  22. Ingelfinger J. A., Goldman P. The serum digitalis concentration--does it diagnose digitalis toxicity? N Engl J Med. 1976 Apr 15;294(16):867–870. doi: 10.1056/NEJM197604152941603. [DOI] [PubMed] [Google Scholar]
  23. Kaloyanides G. J. Renal pharmacology of aminoglycoside antibiotics. Contrib Nephrol. 1984;42:148–167. doi: 10.1159/000409975. [DOI] [PubMed] [Google Scholar]
  24. Kramer W. G., Kolibash A. J., Lewis R. P., Bathala M. S., Visconti J. A., Reuning R. H. Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm. 1979 Feb;7(1):47–61. doi: 10.1007/BF01059440. [DOI] [PubMed] [Google Scholar]
  25. Lehmann C. R., Leonard R. G. Effect of theophylline pharmacokinetic monitoring service on cost and quality of care. Am J Hosp Pharm. 1982 Oct;39(10):1656–1662. [PubMed] [Google Scholar]
  26. McCormack J. P., Schentag J. J. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. Drug Intell Clin Pharm. 1987 Feb;21(2):187–192. [PubMed] [Google Scholar]
  27. Ogilvie R. I., Ruedy J. An educational program in digitalis therapy. JAMA. 1972 Oct 2;222(1):50–55. [PubMed] [Google Scholar]
  28. Reynolds E. H., Shorvon S. D., Galbraith A. W., Chadwick D., Dellaportas C. I., Vydelingum L. Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia. 1981 Aug;22(4):475–488. doi: 10.1111/j.1528-1157.1981.tb06158.x. [DOI] [PubMed] [Google Scholar]
  29. Scott A. K. Management of epilepsy. Br Med J (Clin Res Ed) 1984 Mar 31;288(6422):986–987. doi: 10.1136/bmj.288.6422.986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sheiner L. B., Halkin H., Peck C., Rosenberg B., Melmon K. L. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975 May;82(5):619–627. doi: 10.7326/0003-4819-82-5-619. [DOI] [PubMed] [Google Scholar]
  31. Shinnar S., Vining E. P., Mellits E. D., D'Souza B. J., Holden K., Baumgardner R. A., Freeman J. M. Discontinuing antiepileptic medication in children with epilepsy after two years without seizures. A prospective study. N Engl J Med. 1985 Oct 17;313(16):976–980. doi: 10.1056/NEJM198510173131603. [DOI] [PubMed] [Google Scholar]
  32. Shorvon S. D., Chadwick D., Galbraith A. W., Reynolds E. H. One drug for epilepsy. Br Med J. 1978 Feb 25;1(6111):474–476. doi: 10.1136/bmj.1.6111.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Smith T. W., Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest. 1970 Dec;49(12):2377–2386. doi: 10.1172/JCI106457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Smith T. W. Measurement of serum digitalis glycosides: clinical implications. Circulation. 1971 Feb;43(2):179–182. doi: 10.1161/01.cir.43.2.179. [DOI] [PubMed] [Google Scholar]
  35. Sonnenblick M., Abraham A. S., Meshulam Z., Eylath U. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed) 1983 Apr 2;286(6371):1089–1091. doi: 10.1136/bmj.286.6371.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Spector R., Park G. D., Johnson G. F., Vesell E. S. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988 Apr;43(4):345–353. doi: 10.1038/clpt.1988.42. [DOI] [PubMed] [Google Scholar]
  37. Whiting B., Kelman A. W., Barclay J., Addis G. J. Modelling theophylline response in individual patients with chronic bronchitis. Br J Clin Pharmacol. 1981 Oct;12(4):481–487. doi: 10.1111/j.1365-2125.1981.tb01254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Whiting B., Kelman A. W., Bryson S. M., Derkx F. H., Thomson A. H., Fotheringham G. H., Joel S. E. Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. Br Med J (Clin Res Ed) 1984 Feb 18;288(6416):541–545. doi: 10.1136/bmj.288.6416.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Woodcock A. A., Johnson M. A., Geddes D. M. Theophylline prescribing, serum concentrations, and toxicity. Lancet. 1983 Sep 10;2(8350):610–613. doi: 10.1016/s0140-6736(83)90691-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES